ArticleEsophagus : official journal of the Japan Esophageal Society2025
A comparison of the clinical outcomes of esophagectomy and chemoradiotherapy for patients aged 75 years or older with surgically resectable esophageal squamous cell carcinoma.
Article in Esophagus : official journal of the Japan Esophageal Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeEsophagectomy and chemoradiotherapy (CRT) are the mainstays of treatment for esophageal squamous cell carcinoma (ESCC). Older patients often do not receive full standard treatment due to physiological limitations. This study aimed to assess the long-term prognosis of surgery or non-surgery treatment for older patients with resectable ESCC.
methodsThis retrospective study included 114 patients who underwent esophagectomy (surgery group) and 65 patients who underwent CRT/radiotherapy (RT) (non-surgery group) at Kobe University Hospital. Propensity score matching was performed to identify matched patients in each tumor stage, including those with cT1N0 ESCC and cT1N-positive or cT2/3N-any ESCC. For cT1N0 ESCC, each group (surgery and non-surgery) had 14 patients. For cT1N-positive or cT2/3N-any ESCC, each group had 34 patients.
resultsAfter propensity score matching, for patients with cT1N0, the overall survival (OS) of the surgery group was significantly better than that of the non-surgery groups (p = 0.016). For cT1N-positive or cT2/3N-any patients, no significant differences were observed in OS between the two groups (p = 0.85). Before matching, in patients with cT1N0 ESCC, those who underwent RT alone had worse OS than patients who underwent surgery or CRT (p = 0.0003). In patients with cT1N-positive or cT2/3N-any ESCC, those who underwent RT alone or surgery alone had worse OS than those who underwent neoadjuvant chemotherapy plus surgery or CRT (p = 0.023).
conclusionsPatients who could not receive chemotherapy had poor survival. An appropriate treatment strategy should be considered, taking into account their general condition, especially their ability to receive chemotherapy.
Indexed as
Identifiers
40562945What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.